Yu-Tang Chin

Dr. Yu-Tang Chin

School of Dentistry, National Defense Medical Center, Taipei, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
YHYih Ho
Yih Ho
YYYu-Chen Yang
Yu-Chen Yang
Yu-Tang ChinYu-Tang Chin
Yu-Tang Chin
SCSzu-Yi Chou
Szu-Yi Chou
YCYi-Ru Chen
Yi-Ru Chen
PDPaul J. Davis
Paul J. Davis

1 February 2018 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
TCTsai-Mu Cheng
Tsai-Mu Cheng
Yu-Tang ChinYu-Tang Chin
Yu-Tang Chin
YHYih Ho
Yih Ho
YCYi-Ru Chen
Yi-Ru Chen
YYYung-Ning Yang
Yung-Ning Yang
PDPaul J. Davis
Paul J. Davis

3 August 2020 in Cells
Verified
Journal Article
Open access
PDF file
THTung-Yung Huang
Tung-Yung Huang
TCTung-Cheng Chang
Tung-Cheng Chang
Yu-Tang ChinYu-Tang Chin
Yu-Tang Chin
YPYi-Shin Pan
Yi-Shin Pan
WCWong-Jin Chang
Wong-Jin Chang
PDPaul J. Davis
Paul J. Davis
The property of drug-resistance may attenuate clinical therapy in cancer cells, such as chemoresistance to gefitinib in colon cancer cells. In previous studies, overexpression of PD-L1 causes proliferation and metastasis in cancer cells; therefore, the PD-L1 pathway allows tumor cells to exert an adaptive resistance mechanism in vivo. Nano-diamino-tetrac (NDAT) has been shown to enhance the anti-proliferative effect induced by first-line chemotherapy in various types of cancer, including colorectal cancer (CRC). In this work, we attempted to explore whether NDAT could enhance the anti-proliferative effect of gefitinib in CRC and clarified the mechanism of their interaction. The MTT assay was utilized to detect a reduction in cell proliferation in four primary culture tumor cells treated with gefitinib or NDAT. The gene expression of PD-L1 and other tumor growth-related molecules were quantified by quantitative polymerase chain reaction (qPCR). Furthermore, the identification of PI3K and PD-L1 in treated CRC cells were detected by western blotting analysis. PD-L1 presentation in HCT116 xenograft tumors was characterized by specialized immunohistochemistry (IHC) and the hematoxylin and eosin stain (H&E stain). The correlations between the change in PD-L1 expression and tumorigenic characteristics were also analyzed. (3) The PD-L1 was highly expressed in Colo_160224 rather than in the other three primary CRC cells and HCT-116 cells. Moreover, the PD-L1 expression was decreased by gefitinib (1 µM and 10 µM) in two cells (Colo_150624 and 160426), but 10 µM gefitinib stimulated PD-L1 expression in gefitinib-resistant primary CRC Colo_160224 cells. Inactivated PI3K reduced PD-L1 expression and proliferation in CRC Colo_160224 cells. Gefitinib didn’t inhibit PD-L1 expression and PI3K activation in gefitinib-resistant Colo_160224 cells. However, NDAT inhibited PI3K activation as well as PD-L1 accumulation in gefitinib-resistant Colo_160224 cells. The combined treatment of NDAT and gefitinib inhibited pPI3K and PD-L1 expression and cell proliferation. Additionally, NDAT reduced PD-L1 accumulation and tumor growth in the HCT116 (K-RAS mutant) xenograft experiment. (4) Gefitinib might suppress PD-L1 expression but did not inhibit proliferation through PI3K in gefitinib-resistant primary CRC cells. However, NDAT not only down-regulated PD-L1 expression via blocking PI3K activation but also inhibited cell proliferation in gefitinib-resistant CRCs.

16 July 2013 in Phytomedicine
Verified
Journal Article
Closed access
HTHsiao-Pei Tu
Hsiao-Pei Tu
MFMartin M. Fu
Martin M. Fu
PKPo-Jan Kuo
Po-Jan Kuo
Yu-Tang ChinYu-Tang Chin
Yu-Tang Chin
CCCheng-Yang Chiang
Cheng-Yang Chiang
EFEarl Fu
Earl Fu

27 July 2017 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
Yu-Tang ChinYu-Tang Chin
Yu-Tang Chin
LWLe-Ming Wang
Le-Ming Wang
MHMeng-Ti Hsieh
Meng-Ti Hsieh
YSYa-Jung Shih
Ya-Jung Shih
ANAndré Wendindondé Nana
André Wendindondé Nana
Hung-Yun LinHung-Yun Lin
Hung-Yun Lin
Obesity and its comorbidities constitute a serious health burden worldwide. Leptin plays an important role in diet control; however, it has a stimulatory potential on cancer cell proliferation. The OB3 peptide, a synthetic peptide, was shown to be more active than leptin in regulating metabolism but with no mitogenic effects in cancer cells. In this study, we investigated the proliferative effects, gene expressions and signaling pathways modulated by leptin and OB3 in human ovarian cancer cells. In addition, an animal study was performed. Leptin, but not OB3, induced the proliferation of ovarian cancer cells. Interestingly, OB3 blocked the leptin-induced proliferative effect when it was co-applied with leptin. Both leptin and OB3 activated the phosphatidylinositol-3-kinase (PI3K) signal transduction pathway. In addition, leptin stimulated the phosphorylation of signal transducer and activator of transcription-3 (STAT3) Tyr-705 as well as estrogen receptor (ER)α, and the expression of ERα-responsive genes. Interestingly, all leptin-induced signal activation and gene expressions were blocked by the co-incubation with OB3 and the inhibition of extracellular signal-regulated kinase (ERK)1/2. Coincidently, leptin, but not OB3, increased circulating levels of follicle-stimulating hormone (FSH) which is known to play important roles in the initiation and proliferation of ovarian cancer cells. In summary, our findings suggest that the OB3 peptide may prevent leptin-induced ovarian cancer initiation and progression by disrupting leptin-induced proliferative signals via STAT3 phosphorylation and ERα activation. Therefore, the OB3 peptide is a potential anticancer agent that might be employed to prevent leptin-induced cancers in obese people.

2 July 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
CHCHI-HUNG HUANG
CHI-HUNG HUANG
THTung-Yung Huang
Tung-Yung Huang
WCWong-Jin Chang
Wong-Jin Chang
YPYi-Shin Pan
Yi-Shin Pan
HCHung-Ru Chu
Hung-Ru Chu
KWKuan Wang
Kuan Wang
Background: Heteronemin, a marine sesterterpenoid-type natural product, possesses an antiproliferative effect in cancer cells. In addition, heteronemin has been shown to inhibit p53 expression. Our laboratory has demonstrated that the thyroid hormone deaminated analogue, tetrac, activates p53 and induces antiproliferation in colorectal cancer. However, such drug mechanisms are still to be studied in oral cancer cells. Methods: We investigated the antiproliferative effects by Cell Counting Kit-8 and flow cytometry. The signal transduction pathway was measured by Western blotting analyses. Quantitative PCR was used to evaluate gene expression regulated by heteronemin, 3,3’,5,5’-tetraiodothyroacetic acid (tetrac), or their combined treatment in oral cancer cells. Results: Heteronemin inhibited not only expression of proliferative genes and Homo Sapiens Thrombospondin 1 (THBS-1) but also cell proliferation in both OEC-M1 and SCC-25 cells. Remarkably, heteronemin increased TGF-β1 expression in SCC-25 cells. Tetrac suppressed expression of THBS-1 but not p53 expression in both cancer cell lines. Furthermore, the synergistic effect of tetrac and heteronemin inhibited ERK1/2 activation and heteronemin also blocked STAT3 signaling. Combined treatment increased p53 protein and p53 activation accumulation although heteronemin inhibited p53 expression in both cancer cell lines. The combined treatment induced antiproliferation synergistically more than a single agent. Conclusions: Both heteronemin and tetrac inhibited ERK1/2 activation and increased p53 phosphorylation. They also inhibited THBS-1 expression. Moreover, tetrac suppressed TGF-β expression combined with heteronemin to further enhance antiproliferation and anti-metastasis in oral cancer cells.